The Cancer Treatment Centers of America (CTCA) is putting into operation a new retreatment regimen for Cancer. The new treatment program called The Clinical Pathways program is predicted to be a big boost to the treatment of Cancer.
This is because this treatment will allow the physician to continue with his/her workflow without disrupting the course of treatment. According to the Chief Medical Officer of CTCA Southeastern Regional Medical Center, George Danekar Jr. MD revealed that the new regimen reduces the risk of possible guessing by a clinician who may be overwhelmed by emerging cancer data and research. CTCA has also authenticated Clinical Pathways. The cancer body came up with treatment options for cancer patients to select from to safeguard their safety and efficiency.
CTCA came up with the treatment regimen after collaborating with Allscripts and NantHealth. It essentially means that evil which is a NantHealth product will access clinical workflows in Allscripts Sunrise electronic health record (EHR). Numerous American oncologists came together to come up with NantOS which is the clinical operating system. The interface has an all inclusive compilation of emerging care data for cancer.
The Clinical Pathways program was created by putting the patient first. It has included all the latest research in cancer. In addition to this, it also includes complementary therapies and treatment regimens.
About Cancer Treatment Centers Of America (Ctca)
CTCA is dedicated to fighting cancer in America. The treatment center uses an integrated method to deal with cancer. Some of the approaches that the non-profit network employs include radiation, immunotherapy, and chemotherapy. However, the CTCA also uses various therapies to manage their side effects of cancer and some of the treatments.CTCA operates five hospitals. The headquarters of the establishment is in Boca Raton, Florida. Richard J Stephenson started the establishment. This is after his mother died in the hands of cancer without getting adequate treatment options.